Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19 (COMET-PEAK)
This is a phase 2 study in which 40 subjects with coronavirus disease 2019 (COVID-19) will receive VIR-7831 (Gen1) or VIR-7831 (Gen2) and will be assessed for safety, tolerability, and pharmacokinetics.
Search
Vaccines for Travel
Taking a trip? We'll help you get connected with your local travel vaccination provider.
Precision Vax is not liable or responsible for the content, information, security, or failure of any products or services promoted or advertised on third party sites.